SS
ROIV icon

Steve Schonfeld’s Roivant Sciences ROIV Stock Holding History

Steve Schonfeld’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$569K Sell
16,079
-37,809
-70% -$1.12M ﹤0.01% 1751
2026
Q1 		$1.49M Buy
+53,888
New +$1.38M 0.01% 929
2025
Q4 		– Sell
-178,965
Closed -$2.71M – 2518
2025
Q3 		$2.71M Buy
178,965
+163,451
+1,054% +$2.02M 0.02% 879
2025
Q2 		$175K Sell
15,514
-52,800
-77% -$572K ﹤0.01% 1803
2025
Q1 		$689K Sell
68,314
-3,086
-4% -$33.4K ﹤0.01% 1445
2024
Q4 		$845K Sell
71,400
-283,295
-80% -$3.35M ﹤0.01% 1190
2024
Q3 		$4.09M Buy
354,695
+233,377
+192% +$2.66M 0.03% 612
2024
Q2 		$1.28M Sell
121,318
-662,449
-85% -$7.26M 0.01% 1093
2024
Q1 		$8.26M Buy
783,767
+699,227
+827% +$7.54M 0.05% 445
2023
Q4 		$949K Buy
+84,540
New +$824K 0.01% 1055
2023
Q1 		– Sell
-303,215
Closed -$2.42M – 2568
2022
Q4 		$2.42M Buy
+303,215
New +$1.69M 0.02% 743
2022
Q2 		– Sell
-43,500
Closed -$215K – 2924
2022
Q1 		$215K Buy
+43,500
New +$287K ﹤0.01% 1908

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Steve Schonfeld's ROIV Position: Q2 2026 in Review

Steve Schonfeld reduced its Roivant Sciences (ROIV) stake by 70% in Q2 2026, selling an estimated $1.12M and leaving 16,079 shares worth $569K. The position accounts for ﹤0.01% of the portfolio, ranked #1751.

Steve Schonfeld first reported a position in ROIV in Q1 2022 and has held it in 12 quarters since. The position peaked at $8.26M in Q1 2024. 495 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Steve Schonfeld held 16,079 shares of Roivant Sciences worth $569K as of Q2 2026.
  • Steve Schonfeld sold 37,809 Roivant Sciences shares in Q2 2026, an estimated $1.12M.
  • Roivant Sciences made up ﹤0.01% of Steve Schonfeld's portfolio in Q2 2026, its #1751 holding.
  • Steve Schonfeld first reported a position in Roivant Sciences in Q1 2022 and has held it in 12 quarters since.
  • Steve Schonfeld's Roivant Sciences position peaked at $8.26M in Q1 2024.
  • 495 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.